Dr. Drake on Immunotherapy Side Effects in Genitourinary Cancers

Charles G. Drake, MD, PhD
Published: Friday, Mar 03, 2017



Charles G. Drake, MD, PhD, director of Genitourinary Oncology, NewYork-Presbyterian/Columbia University Medical Center and co-director of Columbia’s Cancer Immunotherapy Programs, discusses the side effects associated with immunotherapy in genitourinary cancers.

Although the rate of adverse events (AE) is lower in immunotherapy than in chemotherapy, the side effect profile can still be severe. AEs such as colitis and pneumonitis need to be watched carefully, says Drake, as they can potentially be fatal if left untreated.

Drake says that physicians need to be aware of, and manage, these autoimmune AEs and inform their patients that if they are feeling symptomatic to report it, as it may be more serious than the flu. Steroids are a viable and effective option to treat these AEs, he adds, and will not hinder tumor shrinkage.
 
SELECTED
LANGUAGE


Charles G. Drake, MD, PhD, director of Genitourinary Oncology, NewYork-Presbyterian/Columbia University Medical Center and co-director of Columbia’s Cancer Immunotherapy Programs, discusses the side effects associated with immunotherapy in genitourinary cancers.

Although the rate of adverse events (AE) is lower in immunotherapy than in chemotherapy, the side effect profile can still be severe. AEs such as colitis and pneumonitis need to be watched carefully, says Drake, as they can potentially be fatal if left untreated.

Drake says that physicians need to be aware of, and manage, these autoimmune AEs and inform their patients that if they are feeling symptomatic to report it, as it may be more serious than the flu. Steroids are a viable and effective option to treat these AEs, he adds, and will not hinder tumor shrinkage.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Community Practice Connections™: Emerging Paradigm Shifts in Renal Cell Carcinoma: A Critical Assessment of Adjuvant Treatment DataApr 30, 20191.5
Publication Bottom Border
Border Publication
x